Objective To develop a questionnaire (“A14”) for the description of adherence and individual barriers as basis for adherence-enhancing interventions in the clinical and pharmaceutical setting, and to compare it to the validated German MMAS (Morisky Medication Adherence Scale). Method Fourteen questions with a 5-item likert-scale from “never” (4) to “very often” (0) were given to 150 medical inpatients. According to their score, patients were classified into non-adherent (score <50) or adherent (score 50–56). On the dichotomous MMAS, “yes” is scored 0 and “no” 1 point, a total score of 4 indicating adherence. Patients with complete scales were compared with the remaining patients regarding socio-demographic factors. Descriptive statistics, Cronbach’s Alpha, Spearman correlation, and κ were computed. Results Eighty-three participants completed both scales. Patients with missing values differed significantly regarding age, education, and adherence according to MMAS. Cronbach’s Alpha for A14 was 0.861. MMAS and A14 median total scores were 4 and 52, respectively. About 39.5% of patients were non-adherent as per MMAS compared to 40% as per A14; κ was 0.262 (P = 0.016). The total scores correlated with a Rho-value of 0.43 (P < 0.001). Conclusion The A14-scale showed good internal consistency and a significant correlation with the MMAS suggesting that it merits further investigation.
A14-scale Drug therapy German language Patient compliance Psychometry Questionnaire Validation
This is a preview of subscription content, log in to check access.
We would like to thank all patients taking part in the study and the ward staff of “Siebeck” for logistical support. Our gratitude goes to RN Barbara Williams and Prof. Ingeborg Walter-Sack for their assistance in the forward-backward-translation of the A14-scale.
This work was in part supported by the AOK Baden-Württemberg Health Insurance Company.
Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107–16. doi:10.1001/jama.289.9.1107.CrossRefPubMedGoogle Scholar
Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Gortz A. Costs of type 2 diabetes in Germany. Results of the CODE-2 study. Dtsch Med Wochenschr. 2001;18(126):585–9. doi:10.1055/s-2001-14102.CrossRefGoogle Scholar